EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024

Amrutha S Alibilli iD, Vidur Jain iD, Heran Mane iD, Xiaohe Yue iD, Alexandria Ratzki-Leewing iD, Junaid S Merchant iD, Shaniece Criss iD, Quynh C Nguyen iD, Rozalina G McCoy iD, Thu T Nguyen iD

JMIR Infodemiology · 24.07.2025 · 5 · e73619-e73619

DOI: 10.2196/73619 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JMIR Infodemiology, online erschienen am 24.07.2025. Verfasst von Amrutha S Alibilli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, University of Maryland, College Park, 4254 Stadium Drive, College Park, 20742, United States, 1 301-405…. Hauptthemen laut MEDLINE: Social Media, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, National Institutes of Health..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In recent years, there has been a dramatic increase in the popularity and use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. As such, it is essential to understand users’ real-world discussions of short-term, long-term, and co-occurrent adverse events associated with currently used GLP-1 RA medications.

Objective

This study aims to quantitatively analyze temporal and co-occurrent GLP-1 RA adverse event trends through discussions of GLP-1 RA weight loss medications on Facebook from 2022 to 2024.

Methods

We collected 64,202 Facebook posts (59,293 posts after removing duplicate posts) from January 1, 2022, to May 31, 2024, through CrowdTangle, a public insights tool from Meta. Using English language social media posts from the United States, we examined discussions of adverse event mentions for posts referencing 7 GLP-1 RA weight loss product categories (ie, semaglutide, Ozempic, Wegovy, tirzepatide, Mounjaro, Zepbound, and GLP-1 RA as a class). All analyses were conducted using Python (version 3; Python Software Foundation) in a Google Colab environment.

Results

Temporal time series analysis revealed that the GLP-1 RAs’ adverse event mentions on social media aligned with several key events: the Food and Drug Administration’s approval of Wegovy for pediatric weight management in December 2022, increased media coverage in August 2023, celebrity endorsement in December 2023, and Medicare Part D coverage expansion for weight loss medications in March 2024. Gastrointestinal (GI)–related adverse events (general term) were most prevalent for posts mentioning the GLP-1 RA class (210/4885, 4.30%) and Mounjaro (241/4031, 5.98%). In contrast, the most prevalent adverse event mentions noted for tirzepatide were headache (78/4202, 1.86%) and joint pain (71/4202, 1.69%). Hypertension (13/1769, 0.73%) was frequently mentioned in Zepbound posts, while pancreatitis was commonly associated with Mounjaro posts (44/4031, 1.08%), and 2.85% (139/4885) of posts broadly referring to the GLP-1 RA class. Furthermore, an integrated node network analysis revealed 3 distinct GLP-1 RA adverse events–mentioned clusters: cluster 1 (purple) contained allergies, anxiety, depression, chronic obstructive pulmonary disease, fatigue, fever, hypertension, indigestion, insomnia, gastroesophageal reflux disease, hives, swelling, restlessness, and seizures. Cluster 2 (pink) contained constipation, dehydration, headache, diarrhea, dizziness, hypoglycemia, sweating, and jaundice. Cluster 3 (brown) contained GI symptoms, such as nausea, pancreatitis, rash, and vomiting. The GI symptoms, such as nausea, vomiting, pancreatitis, diarrhea, and indigestion, were strongly associated together (≥100 co-occurrence mentions), while the mentioned neurological symptoms, such as anxiety, depression, and insomnia, were highly correlated with each other (50‐100 co-occurrence mentions).

Conclusions

This social media study highlights the adverse event mention patterns for posts referencing GLP-1 RA medications. While further research is needed to rigorously examine and validate these findings, this study demonstrates the importance of monitoring social media discussions to predict novel, underreported, or rare drug adverse events, thereby improving patient care, clinical research, and health policy interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Social MediaGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsDrug-Related Side Effects and Adverse ReactionsHumansUnited StatesGlucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP-1 RAsMounjaroOzempicWegovyZepboundadverse eventsobesity managementsemaglutidesocial mediatirzepatideweight loss medication

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, University of Maryland, College Park, 4254 Stadium Drive, College Park, 20742, United States, 1 301-405-6589.
  • Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, United States.
  • University of Maryland Institute for Health Computing, North Bethesda, MD, United States.
  • Department of Health Sciences, Furman University, Greenville, SC, United States.
  • National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, United States.
  • Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States.

ORCID-Profile: Amrutha S Alibilli, Vidur Jain, Heran Mane, Xiaohe Yue, Alexandria Ratzki-Leewing, Junaid S Merchant, Shaniece Criss, Quynh C Nguyen, Rozalina G McCoy, Thu T Nguyen

Förderung

  • NIMHD NIH HHS
  • National Institutes of Health.

Zitieren

APA

Alibilli, A. S., Jain, V., Mane, H., Yue, X., Ratzki-Leewing, A., Merchant, J. S., Criss, S., Nguyen, Q. C., McCoy, R. G., & Nguyen, T. T. (2025). Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024. JMIR Infodemiology, 5, e73619-e73619. https://doi.org/10.2196/73619

Vancouver

Alibilli AS, Jain V, Mane H, Yue X, Ratzki-Leewing A, Merchant JS, et al. Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024. JMIR Infodemiology. 2025;5:e73619-e73619. doi:10.2196/73619

BibTeX
@article{Alibilli2025,
  author = {Alibilli, Amrutha S and Jain, Vidur and Mane, Heran and Yue, Xiaohe and Ratzki-Leewing, Alexandria and Merchant, Junaid S and Criss, Shaniece and Nguyen, Quynh C and McCoy, Rozalina G and Nguyen, Thu T},
  title = {Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024},
  journal = {JMIR Infodemiology},
  year = {2025},
  volume = {5},
  pages = {e73619--e73619},
  doi = {10.2196/73619}
}
Kostenlos starten →